Based on your answers, here is information for when cancer cells remain after treatment and surgery.
As you read your results, look out for underlined words that you can click on to see the term defined.
If you have residual disease, your doctor may recommend:
People with HER+ early breast cancer who had treatment before surgery (including a taxane and trastuzumab) and there is cancer remaining in the tissue removed during surgery.
KADCYLA is used after surgery and is given as an intravenous (IV) infusion for 30-90 minutes.*
For additional Important Safety Information, including most serious side effects, click here.
Stay on this page to learn more about KADCYLA and how it may be able to help.
*This does not account for observation time and other aspects of treatment. Actual clinic time may vary.
Remember, this site is for educational purposes only. Your primary sources of information should always be your doctor and the professionals who make up your healthcare team. Only they can give you medical advice about HER2+ early breast cancer and treatment.
1,486 people with certain types of HER2+ early breast cancer who:
Received neoadjuvant treatment including a taxane and trastuzumab (Herceptin)
Had surgery
To find out which adjuvant treatment, KADCYLA or Herceptin, was better at keeping people cancer free.
KADCYLA significantly lowered the chance of cancer coming back compared to Herceptin, according to a comparison study.
88% of people who received KADCYLA after surgery were still cancer‑free 3 years after the study was started.
77% of people who received Herceptin were still cancer‑free 3 years after the study was started.
The chance of cancer coming back was lowered by 50% for people who received KADCYLA compared to people who received Herceptin.
At the time of this data review, it was too early in the study to determine if people lived longer with KADCYLA. However, people in the study will continue to be followed and evaluated.
What are the most serious side effects of KADCYLA?
What are other possible serious side effects of KADCYLA?
See additional Important Safety Information below.
The dosing schedule for KADCYLA is organized by cycle. For example, KADCYLA is given once every 3 weeks. That is 1 cycle.
You will receive KADCYLA for 14 cycles (42 weeks), unless side effects become too difficult to manage or the cancer comes back sooner.
As you read your results, look out for underlined words that you can click on to see the term defined.
We want to help provide you with the information you need to feel empowered throughout your treatment for HER2+ EBC.
Here are some starter questions to begin a conversation with your doctor or healthcare team:
What does PERJETA treat?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
Important Safety Information
Side effects may vary based on chemotherapy regimen.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
What does PHESGO treat?
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:
Important Safety Information
What are the most common side effects?
The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PHESGO.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
Who is KADCYLA for?
Early Breast Cancer
KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Important Safety Information
What is the most Important Safety Information I should know about KADCYLA?
Liver problems
Heart problems
Pregnancy
Contact your doctor right away if you experience symptoms associated with these side effects.
What are the additional possible serious side effects of KADCYLA?
Lung problems
Infusion-related reactions
Serious bleeding
Low platelet count
Nerve damage
Skin reactions around the infusion site
What are the most common side effects of KADCYLA?
The most common side effects in people taking KADCYLA for early breast cancer are:
You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
Talk to a healthcare professional for more information about the benefits and risks of KADCYLA.
Please see full Prescribing Information for Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
What does PERJETA treat?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
Important Safety Information
Side effects may vary based on chemotherapy regimen.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.